Form 4: BioAge Labs Director Patrick Enright Granted 22,000 Stock Options

BioAge Labs, Inc. Director Patrick G. Enright was granted 22,000 stock options with an exercise price of $4.44 per share, vesting over the next year.

Summary

• Patrick G. Enright, a Director of BioAge Labs, Inc. (BIOA), was granted 22,000 stock options.
• The options have an exercise price of $4.44 per share.
• The grant date for these options was June 5, 2025.
• The options will vest on the earlier of the next annual meeting of stockholders or the one-year anniversary of the grant date (June 5, 2026), contingent on continued service.
• The options expire on June 4, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for aligning interests and incentivizing long-term performance, reflecting standard corporate compensation practices.

Positives

• Grant of 22,000 stock options to Director Patrick G. Enright aligns his interests with shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period (until June 4, 2035), providing a long-term incentive for the director.

Negatives

• NA

Risks

• NA

Future Outlook

The grant of long-term stock options to a director indicates a continued commitment to aligning management incentives with future company growth and shareholder value creation over the next decade.

Management Comments

• The filing was signed by Dov A. Goldstein as attorney-in-fact for Patrick G. Enright.

Industry Context

The granting of stock options to directors is a common practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice in publicly traded companies, particularly within the life sciences sector, comparable to compensation structures seen at companies like Moderna (MRNA) or Regeneron Pharmaceuticals (REGN) for their non-executive directors, though the specific number and exercise price are company-specific.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with long-term shareholder value creation.

Next Steps

• The options will vest on the earlier of the next annual meeting of BioAge Labs' stockholders or June 5, 2026, subject to continued service.
• Patrick G. Enright may exercise these options at any time after vesting and before the expiration date of June 4, 2035.

Key Dates

Recommendation

Keywords

BioAge Labs, BIOA, stock options, insider transaction, SEC filing, Form 4, director compensation, equity grant